Introduction: Ovarian cancer is the leading cause of death from gynecologic cancers, in
fact,> 80% of cases are diagnosed as advanced-stage disease associated with a high …

Abstract HE4 (human epididymis protein 4) is overexpressed in both ovarian and
endometrial cancers. Levels of the shed HE4 protein are elevated in sera from ovarian and …

Ovarian cancer (OVC), the most lethal form of all gynecological cancers, is a big threat to
women's health. Late diagnosis at the advanced stages is one of the major reasons for the …

Objectives To assess the clinical value of early clearance of HE4 and CA125 for platinum
sensitivity and prognosis in patients with ovarian cancer. Method HE4 and CA125 value …

Aim Human epididymis protein 4 (HE4) is a novel biomarker for epithelial ovarian cancer.
This study was designed to evaluate the role of HE4 in chemo‐response against anti‐cancer …

Background HE4, a novel tumor marker for detecting ovarian cancer, has been recently
applied to clinical practice. However, the comprehensive evaluation of HE4 combined with …

Purpose of investigation: HE4 (human epididymis protein 4) is suggested to be used as a
potential new biomarker to identify ovarian malignancies from benign adnexal masses. The …

Clinical utility of new biomarkers often requires the identification of their optimal threshold.
This external validation study was conducted to assess the performance of the preoperative …

Hydroxylatopillar [6] arene (HP6) has been used as a stable ligand for the synthesis of gold
nanoparticles (AuNPs). HP6 with excellent molecular recognition capability will securely …

Background This study assessed the prognostic value of HE4 marker measurements at
various stages of first-line chemotherapy for ovarian cancer. Methods The study consisted of …